Could a new therapy eliminate HIV in newborns?
Researchers have discovered a groundbreaking three-part therapy that completely clears HIV from newborn primates when administered shortly after infection. This innovative approach combines standard antiretroviral drugs, broadly neutralizing antibodies, and an experimental antibody called leronlimab. Remarkably, this combination was effective even though none of the treatments worked alone, raising hopes for a potential one-time cure for infants exposed to HIV.
This finding is significant for global health, especially considering that over 120,000 babies are infected with HIV each year. For many living with the virus, lifelong treatment is necessary to manage the infection. If this new therapy proves effective in humans, it could drastically change the landscape of HIV treatment, allowing for a permanent solution rather than ongoing medication. The researchers are particularly optimistic about moving to clinical trials, which could eventually lead to a treatment that benefits not just newborns but also newly exposed adults.
The research, conducted by Oregon Health & Science University, involved nonhuman primates and demonstrated strong results within a short time frame—specifically, within three days of infection. While this study shows promise, it’s important to note that it is still in the early stages, and further testing in humans is required to confirm its effectiveness. The researchers are also exploring how long after infection this treatment could still be effective, which could broaden its applicability.
For those interested in HIV treatment advancements, this study highlights the potential for innovative therapies that could change lives. As research progresses, staying informed about new developments in HIV treatments may be beneficial, especially if you or someone you know is affected by the virus.